Centre for Targeted Therapy


The Centre for Targeted Therapy (CTT) is the Garvan Institute's centre of excellence for the development of new biological drugs. Biotechnology drugs, such as the monoclonal antibodies Pembrolizumab (Keytruda) and Adalimumab (Humira), are revolutionising the treatment of cancer and inflammatory conditions. 


The Centre operates state of the art equipment required for the measurement of macromolecular interactions and for the development and characterisation of candidate drugs, including surface plasmon resonance, biolayer interferometry and bioreactor systems.

Research scope

Research at the CTT focuses on improving the transition of basic research into into drug candidates, products and treatments. The Centre is developing resources and events for the community to learn about biologics.

Current positions vacant

PhD in Antibody Therapeutics and Targeted Cancer Therapy


Senior Research Officers:

Dr Jake Henry

Research Assistants:

Jennifer Jackson 
Helen Lenthall